Early Phase Development and CDMOs in the Outsourcing Landscape

In this Drug Digest video, our speakers will discuss early phase development in outsourcing and the role of CDMOs in the typical business model.

Register Free: https://www.pharmtech.com/pt_w/outsourcing-landscape

Event Overview

Contract research organization (CRO) services are continuing to grow at an immense pace, driven in part by rapidly evolving technologies used in drug discovery and development. According to market research, the CRO services sector is forecast to be worth $127.3 billion by 2028, representing a double digit (10.7%) compound annual growth rate (1).

As the bio/pharma industry gravitates towards more complex clinical pipelines, outsourcing has been a necessity for many as it can control costs/minimize internal staff and resources, for example, in addition to getting products out in the most efficient way (1,2). An area that is not highlighted as much in industry commentary is the early phase development of outsourcing and what needs to be improved to remain in line with the fast pace of change happening within this industry.

In this Drug Digest video, Chris Moreton, FinnBrit Consulting, will provide expert insights into what happens in early phase development and highlight the benefits and challenges of this step in the outsourcing process.

• Markets and Markets. Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area (Oncology, Infectious Disease, Neurology, Immunology, Hematology, Vaccines, Cell and Gene Therapy), End User, and Region—Global Forecast to 2028. Market Report, February 2023. https://www.marketsandmarkets.com/Market-Reports/contract-research-organization-service-market-167410116.html
• Murphy, J. The Growth and Emergence of Technology in the Outsourcing Space. Pharmaceutical Technology, 2023, 47 (1), 40–41.

Key Learning Objectives:

• The ability to identify new trends in the outsourcing sector
• Problem solving: ability to learn new development routes to address complex therapies needs
• Early phase development: ability to develop a new perspective of the steps CROs/CDMOs take in this stage of development
• Awareness: ability to successfully prepare and train future hires in the CRO space

Who Should Attend:

• Outsourcing/procurement professionals
• CROs
• CDMOs
• Bio/pharma developers

Speakers

Chris Moreton, PhD
FinnBrit Consulting

Christine Fürst
Senior Director
Key Account Management Europe

Register Free: https://www.pharmtech.com/pt_w/outsourcing-landscape

Sponsors